Risk Factors and Indications for Colectomy in Ulcerative Colitis Patients Are Different According to Patient's Clinical Background
Overview
Authors
Affiliations
Purpose: Despite progress in medical treatment for ulcerative colitis, a considerable fraction of ulcerative colitis patients undergo colectomy. We analyzed the clinical variables of ulcerative colitis patients and determined the risk factors and indications for colectomy.
Methods: The clinical records of 981 consecutive Japanese patients with ulcerative colitis were reviewed both retrospectively and prospectively.
Results: Of 981 patients with ulcerative colitis, 85 patients underwent colectomy. Multivariate analysis indicated that male gender (risk ratio, 2.16; 95 percent confidence interval, 1.37-3.42), onset year during and after 2000 (risk ratio, 2.85; 95 percent confidence interval, 1.31-6.22), severe disease activity (risk ratio, 2; 95 percent confidence interval, 1.15-3.48), corticosteroid resistance (risk ratio, 7.05; 95 percent confidence interval, 4.29-11.59), and complications because of corticosteroid administration (risk ratio, 3.55; 95 percent confidence interval, 2.08-6.06) were significant risk factors for colectomy. In patients with disease duration of more than five years, only corticosteroid resistance and complications because of corticosteroid were significant risk factors for colectomy. When we stratified indications for colectomy for the 85 cases via patient disease duration, massive hemorrhage was a relatively frequent cause of colectomy in patients with a disease duration of less than five years (P = 0.091). On the other hand, colon dysplasia or cancer was a major cause for colectomy in patients with a disease duration of more than ten years (P = 0.0001).
Conclusions: In ulcerative colitis patients, the risk factors and indications for colectomy were different according to the patient's clinical background. Our findings may help to predict patients with ulcerative colitis who have a high risk for colectomy.
An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis.
Ferretti F, Cannatelli R, Monico M, Maconi G, Ardizzone S J Clin Med. 2022; 11(9).
PMID: 35566428 PMC: 9104748. DOI: 10.3390/jcm11092302.
Tanaka M, Takagi T, Naito Y, Uchiyama K, Hotta Y, Toyokawa Y JGH Open. 2021; 5(3):377-381.
PMID: 33732885 PMC: 7936618. DOI: 10.1002/jgh3.12506.
Early Intervention in Ulcerative Colitis: Ready for Prime Time?.
Solitano V, DAmico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S J Clin Med. 2020; 9(8).
PMID: 32823997 PMC: 7464940. DOI: 10.3390/jcm9082646.
LaChapelle C, Whitney S, Aalberg J, Plietz M, Reppucci M, Salk A J Gastrointest Surg. 2019; 24(4):933-938.
PMID: 31823318 DOI: 10.1007/s11605-019-04481-w.
The Role of Early Biologic Therapy in Inflammatory Bowel Disease.
Berg D, Colombel J, Ungaro R Inflamm Bowel Dis. 2019; 25(12):1896-1905.
PMID: 30934053 PMC: 7185690. DOI: 10.1093/ibd/izz059.